Senate votes to confirm Azar as health secretary

Published 01/24/2018, 03:08 PM
© Reuters. Azar II testifies before the Senate Finance Committee in Washington
LLY
-

WASHINGTON (Reuters) - The U.S. Senate on Wednesday voted to confirm former pharmaceutical industry executive and lobbyist Alex Azar as the next Health and Human Services secretary.

Azar will oversee the Trump administration's response to the opioid epidemic, its efforts to weaken the Affordable Care Act, commonly called Obamacare, and address rising prescription drug prices. The Senate voted 55-43 in favor of his nomination.

Most Democrats opposed Azar's nomination, and several delivered impassioned speeches on Tuesday and Wednesday that criticized Azar for raising drug prices while he was at U.S. pharmaceutical firm Eli Lilly & Co (N:LLY), where he spent five years as president of its U.S. unit. Several patient and consumer advocacy groups opposed Azar's nomination because of drug price increases at Lilly under his watch.

"Mr. Azar's nomination is a perfect encapsulation of the president's broken promises on prescription drugs and healthcare overall," Democratic Senator Ron Wyden said on Tuesday in a Senate floor speech.

Republicans and some medical groups said Azar, who also served as general counsel and deputy secretary for Health and Human Services under former Republican President George W. Bush, had extensive qualifications for the job.

© Reuters. Azar II testifies before the Senate Finance Committee in Washington

Trump's first health secretary, former U.S. Representative Tom Price, resigned in September amid a furor over his use of expensive taxpayer-funded private charter jets for government travel.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.